TRUE Private Wealth Advisors Has $6.06 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

TRUE Private Wealth Advisors lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 18.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,834 shares of the company's stock after selling 1,524 shares during the period. Eli Lilly and Company accounts for 0.7% of TRUE Private Wealth Advisors' portfolio, making the stock its 25th biggest holding. TRUE Private Wealth Advisors' holdings in Eli Lilly and Company were worth $6,055,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Peterson Financial Group Inc. bought a new position in Eli Lilly and Company in the 3rd quarter valued at about $27,000. MidAtlantic Capital Management Inc. bought a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $30,000. Lynx Investment Advisory bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $32,000. LGT Financial Advisors LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $36,000. Finally, Morton Brown Family Wealth LLC boosted its position in shares of Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company's stock valued at $41,000 after purchasing an additional 15 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Up 0.9 %

Shares of NYSE LLY traded up $7.16 during mid-day trading on Friday, reaching $795.35. The company had a trading volume of 2,206,918 shares, compared to its average volume of 3,213,011. The stock has a fifty day moving average of $851.90 and a two-hundred day moving average of $870.26. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company has a market capitalization of $755.04 billion, a price-to-earnings ratio of 85.98, a PEG ratio of 2.99 and a beta of 0.43. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter in the prior year, the company posted $0.10 EPS. The company's quarterly revenue was up 20.4% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly and Company will post 13.2 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. Eli Lilly and Company's dividend payout ratio is currently 56.22%.

Analyst Ratings Changes

LLY has been the subject of several research reports. Redburn Atlantic upgraded shares of Eli Lilly and Company to a "hold" rating in a research report on Monday, November 4th. Cantor Fitzgerald restated an "overweight" rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating for the company in a research report on Monday, November 4th. Evercore ISI upgraded shares of Eli Lilly and Company to a "hold" rating in a research report on Thursday, September 5th. Finally, Wolfe Research initiated coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an "outperform" rating and a $1,000.00 price objective for the company. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,007.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.